Research Topic

Brain and Leptomeningeal Metastases in Lung Cancer

About this Research Topic

Lung cancer is one of the most frequent malignant tumors worldwide, with 84% of all lung cancers enlisted as non-small cell lung cancers (NSCLCs) and about 13% of them as small-cell lung cancers (SCLCs). The majority of patients with lung cancer present with an advanced stage of the disease when diagnosed. NSCLCs and SCLCs demonstrate high incidence of central nervous system dissemination, with approximately 40% of patients developing brain metastases and a smaller percentage, 3-5%, developing leptomeningeal ones during the course of their disease.

First-line treatment for stage IV NSCLC changed considerably, however treating central nervous system dissemination is still a challenge. This is confirmed also for SCLC where brain metastases present distinct clinical characteristics reflected also in radio and chemo-sensitivity but high aggressiveness with rapid evolution.

The prognosis of patients with central nervous system dissemination from lung cancer is still poor as documented in both retrospective and prospective studies. Patients with brain metastases from NSCLC are usually excluded from clinical trials if not treated, and SCLC ones are also excluded from those on the management of brain metastases due to the different biological behavior of the primary tumor. On the contrary, treatments particularly for stage IV NSCLC and then for advanced SCLC, primarily as a result of a better patient selection on the basis of histology, molecular markers, and because of innovative treatment approaches, are widely improving.

The aim of this Research Topic is to highlight the state of research in advanced lung cancer with central nervous system dissemination focusing also on selected sub-populations such as patients with oncogene-addicted NSCLC, oligo-metastatic NSCLC disease, and patients with brain or leptomeningeal metastasis who underwent immunotherapy or other innovative systemic or local approaches.

We welcome Reviews, Case Reports, and Clinical Studies that aim to frame and deepen this fundamental and challenging topic whilst documenting the state of research and scientific improvements in advanced lung cancer with central nervous system dissemination. We welcome submissions on:
- Epidemiology and biology of brain metastases or leptomeningeal dissemination in lung cancer.
- Advances in imaging of lung cancer brain metastases or leptomeningeal dissemination.
- Critical issues in clinical trial methodology for lung cancer patients with brain or central nervous system dissemination.
- Quality of life of lung cancer patients with brain metastases or leptomeningeal dissemination.
- Focus on elderly lung cancer patients with brain metastases or leptomeningeal dissemination.
- Systemic treatments in patients with oncogene-addicted NSCLC and brain metastases or leptomeningeal dissemination.
- Local approaches for NSCLC patients with brain metastases or leptomeningeal dissemination.
- Immunotherapy in NSCLC patients with brain metastases.
- Management of leptomeningeal metastasis in NSCLC patients.
- Management of SCLC patients with brain metastases or leptomeningeal dissemination.


Keywords: Lung cancer, advanced NSCLC, SCLC, brain metastases, leptomeningeal metastases


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Lung cancer is one of the most frequent malignant tumors worldwide, with 84% of all lung cancers enlisted as non-small cell lung cancers (NSCLCs) and about 13% of them as small-cell lung cancers (SCLCs). The majority of patients with lung cancer present with an advanced stage of the disease when diagnosed. NSCLCs and SCLCs demonstrate high incidence of central nervous system dissemination, with approximately 40% of patients developing brain metastases and a smaller percentage, 3-5%, developing leptomeningeal ones during the course of their disease.

First-line treatment for stage IV NSCLC changed considerably, however treating central nervous system dissemination is still a challenge. This is confirmed also for SCLC where brain metastases present distinct clinical characteristics reflected also in radio and chemo-sensitivity but high aggressiveness with rapid evolution.

The prognosis of patients with central nervous system dissemination from lung cancer is still poor as documented in both retrospective and prospective studies. Patients with brain metastases from NSCLC are usually excluded from clinical trials if not treated, and SCLC ones are also excluded from those on the management of brain metastases due to the different biological behavior of the primary tumor. On the contrary, treatments particularly for stage IV NSCLC and then for advanced SCLC, primarily as a result of a better patient selection on the basis of histology, molecular markers, and because of innovative treatment approaches, are widely improving.

The aim of this Research Topic is to highlight the state of research in advanced lung cancer with central nervous system dissemination focusing also on selected sub-populations such as patients with oncogene-addicted NSCLC, oligo-metastatic NSCLC disease, and patients with brain or leptomeningeal metastasis who underwent immunotherapy or other innovative systemic or local approaches.

We welcome Reviews, Case Reports, and Clinical Studies that aim to frame and deepen this fundamental and challenging topic whilst documenting the state of research and scientific improvements in advanced lung cancer with central nervous system dissemination. We welcome submissions on:
- Epidemiology and biology of brain metastases or leptomeningeal dissemination in lung cancer.
- Advances in imaging of lung cancer brain metastases or leptomeningeal dissemination.
- Critical issues in clinical trial methodology for lung cancer patients with brain or central nervous system dissemination.
- Quality of life of lung cancer patients with brain metastases or leptomeningeal dissemination.
- Focus on elderly lung cancer patients with brain metastases or leptomeningeal dissemination.
- Systemic treatments in patients with oncogene-addicted NSCLC and brain metastases or leptomeningeal dissemination.
- Local approaches for NSCLC patients with brain metastases or leptomeningeal dissemination.
- Immunotherapy in NSCLC patients with brain metastases.
- Management of leptomeningeal metastasis in NSCLC patients.
- Management of SCLC patients with brain metastases or leptomeningeal dissemination.


Keywords: Lung cancer, advanced NSCLC, SCLC, brain metastases, leptomeningeal metastases


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

31 May 2021 Abstract
31 August 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

31 May 2021 Abstract
31 August 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..